Relative Bioavailability and Food Effect Study for GSK163090 in Healthy Male and Female Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

September 20, 2007

Primary Completion Date

November 5, 2007

Study Completion Date

November 5, 2007

Conditions
Depressive Disorder and Anxiety Disorders
Interventions
DRUG

GSK163090 capsule, fasted

GSK163090 will be available as 1 mg hard gelatine white/white opaque capsules. Each subject will receive a single, oral dose of the study medication on the morning of Day 1. The study drug will be administered with approximately 240 milliliters (mL) of water.

DRUG

GSK163090 Tablet, fasted

GSK163090 will be available as 1 mg white coated round tablet. Each subject will receive a single, oral dose of the study medication on the morning of Day 1. The study drug will be administered with approximately 240 mL of water.

DRUG

GSK163090 Tablet, fed

GSK163090 will be available as 1 mg white coated round tablet. Each subject will receive a single, oral dose of the study medication on the morning of Day 1. The study drug will be administered with Food and Drug Administration (FDA) high fat breakfast.

Trial Locations (1)

41460

GSK Investigational Site, Neuss

Sponsors

Lead Sponsor

All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT00536679 - Relative Bioavailability and Food Effect Study for GSK163090 in Healthy Male and Female Volunteers | Biotech Hunter | Biotech Hunter